Navigation Links
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
Date:4/7/2008

DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for oral and poster presentations at the AACR Annual Meeting, which will take place April 12-16 in San Diego, California.

An oral presentation by Dr. Steven Warner will highlight SuperGen's PIM Kinase Inhibitor in cell lines from hematological and solid malignancies. The poster presentations will focus on data concerning many of SuperGen's current oncology programs, including the lead clinical compound, MP-470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.
SuperGen's schedule of presentations is as follows:

Date Time (PDT) Abstract # and Title

Sunday, 8 a.m. - 12 p.m. #671 -- Inhibition of erlotinib resistance

April 13 on HER-family tyrosine kinases by

combination with MP-470, a

multi-targeted TK inhibitor in prostate and

breast cancer

Monday, 1 p.m. - 5 p.m. #2613 -- The dinucleotide prodrug of

April 14 decitabine demonstrated increased in vivo

efficacy due to enhanced drug delivery and

stability

Tuesday, 8 a.m. - noon #4083 -- MP-470, a potent oral Rad51

April 15 suppressor is safe and tolerable in

first-in-human study

Tuesday, 2:25 p.m. - #4974 -- A potent small molecule PIM kinase

April 15 2:40 p.m. inhibitor with activity in cell lines from

(oral presentation) hematological and solid malignancies

Tuesday, 1 p.m. - 5 p.m. #4891 -- Activity of the multi-targeted,

April 15 receptor tyrosine kinase inhibitor MP-470

against synovial sarcoma cells

Wednesday, 8 a.m. - noon #5729 -- Pharmacokinetics of MP-529, a

April 16 selective Aurora A kinase inhibitor, in a

novel subcutaneous delivery system

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development

Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
2. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
3. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
4. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
7. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
8. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
9. Mitchell, Military TBI Task Force Highlight the Importance of Traumatic Brain Injury Research; Mitchell Endorses Ground Breaking Traumatic Brain Injury Study
10. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
11. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 23, 2017  HealthMine surveys with 9,250 ... revealed that health plan members want help from their ... stay engaged in their health, 2) help closing gaps ... platform for health and 5) relevant, real-time guidance. Meeting ... lowering healthcare costs. A Reason ...
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/24/2017)... 24, 2017 The Board of Directors of ... Report 2016 including the complete 2016 Annual Accounts with notes. ... Nordic Nanovector,s website in the section Investor Relations/Reports and presentations/Annual ... ... Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... In just two days, Aqua Design ... garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the original ... (and counting) already backing the campaign. , “We are very grateful for ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June ... ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will present on: ... of cases litigated under ERISA involve claims for long-term disability benefits. This ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... 24, 2017 , ... “Finding Christ Through Social Media: Year ... chronicling the writer’s path toward true communion with God. “Finding Christ Through Social ... the creation of published author Lea Michelle Johnson, a follower of Christ, wife ...
(Date:3/24/2017)... ... , ... “The Communion of Saints: A Pastor’s Potpourri of ... across the United States. “The Communion of Saints” is the creation of ... congregations in seven states throughout his long career of devotion to the church. ...
Breaking Medicine News(10 mins):